<!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pharma Daily Brief | PiercePharma 朝刊</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+JP:wght@400;500;600;700&family=IBM+Plex+Sans:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg-main: #0f1419;
      --bg-card: #1a2332;
      --bg-card-hover: #232f42;
      --text-primary: #e8edf4;
      --text-secondary: #94a3b8;
      --text-muted: #64748b;
      --accent-pipeline: #38bdf8;
      --accent-regulatory: #fb923c;
      --accent-deals: #4ade80;
      --accent-earnings: #a78bfa;
      --border: #2d3a4f;
      --link: #7dd3fc;
      --link-hover: #bae6fd;
    }
    * { box-sizing: border-box; margin: 0; padding: 0; }
    body { font-family: 'IBM Plex Sans', 'Noto Sans JP', sans-serif; background: var(--bg-main); color: var(--text-primary); line-height: 1.6; min-height: 100vh; padding: 24px 16px; }
    .container { max-width: 720px; margin: 0 auto; }
    .header { margin-bottom: 32px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
    .header h1 { font-size: 1.5rem; font-weight: 700; letter-spacing: -0.02em; }
    .header .date { font-size: 0.875rem; color: var(--text-muted); margin-top: 4px; font-weight: 500; }
    .header .subtitle { font-size: 0.8125rem; color: var(--text-secondary); margin-top: 8px; }
    .header .scope { font-size: 0.75rem; color: var(--text-muted); margin-top: 12px; padding: 10px 12px; background: var(--bg-card); border-radius: 6px; border: 1px solid var(--border); line-height: 1.5; }
    .header .scope strong { color: var(--text-secondary); }
    .category-section { margin-bottom: 28px; }
    .category-header { display: flex; align-items: center; gap: 8px; margin-bottom: 12px; font-size: 0.8125rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; }
    .category-header .badge { width: 8px; height: 8px; border-radius: 50%; }
    .category-pipeline .badge { background: var(--accent-pipeline); } .category-pipeline .category-header { color: var(--accent-pipeline); }
    .category-regulatory .badge { background: var(--accent-regulatory); } .category-regulatory .category-header { color: var(--accent-regulatory); }
    .category-deals .badge { background: var(--accent-deals); } .category-deals .category-header { color: var(--accent-deals); }
    .category-earnings .badge { background: var(--accent-earnings); } .category-earnings .category-header { color: var(--accent-earnings); }
    .article-card { background: var(--bg-card); border: 1px solid var(--border); border-left: 3px solid; border-radius: 8px; padding: 16px; margin-bottom: 12px; transition: background 0.2s; }
    .article-card:hover { background: var(--bg-card-hover); }
    .article-card.pipeline { border-left-color: var(--accent-pipeline); }
    .article-card.regulatory { border-left-color: var(--accent-regulatory); }
    .article-card.deals { border-left-color: var(--accent-deals); }
    .article-card.earnings { border-left-color: var(--accent-earnings); }
    .article-card .title { font-size: 1rem; font-weight: 600; margin-bottom: 8px; line-height: 1.4; }
    .article-card .title a { color: var(--text-primary); text-decoration: none; transition: color 0.2s; }
    .article-card .title a:hover { color: var(--link-hover); }
    .article-card .summary { font-size: 0.875rem; color: var(--text-secondary); margin-bottom: 10px; line-height: 1.5; }
    .article-card .meta { display: flex; flex-wrap: wrap; gap: 12px; font-size: 0.75rem; color: var(--text-muted); }
    .article-card .meta span { display: inline-flex; align-items: center; gap: 4px; }
    .article-card .link-wrap { margin-top: 10px; }
    .article-card .link-wrap a { font-size: 0.8125rem; color: var(--link); text-decoration: none; transition: color 0.2s; }
    .article-card .link-wrap a:hover { color: var(--link-hover); text-decoration: underline; }
    .article-card .link-wrap a::after { content: '→'; }
    .importance { display: inline-flex; gap: 2px; }
    .importance .star { color: var(--accent-regulatory); font-size: 0.7rem; }
    .importance .star.empty { color: var(--text-muted); opacity: 0.5; }
    .article-card .meta .region { font-size: 0.7rem; padding: 2px 6px; border-radius: 4px; font-weight: 500; }
    .region-us { background: rgba(56,189,248,0.2); color: var(--accent-pipeline); }
    .region-europe { background: rgba(251,146,60,0.2); color: var(--accent-regulatory); }
    .region-china { background: rgba(74,222,128,0.2); color: var(--accent-deals); }
    @media (max-width: 480px) { body { padding: 16px 12px; } .header h1 { font-size: 1.25rem; } .article-card { padding: 14px; } }
  </style>
</head>
<body>
  <div class="container">
    <header class="header">
      <h1>Pharma Daily Brief</h1>
      <div class="date">2026年02月23日（月）</div>
      <div class="subtitle">パイプライン・規制・M&A・決算｜医薬・バイオ業界の重要ニュース（毎朝更新）</div>
      <div class="scope">
        <strong>対象地域：</strong>約9割は米国。欧州はノボノルディスク、ブリストルマイヤーズスクイーブ、サノフィ、ロッシュ、バイエルなど大手の重要ニュースを追加。中国は個別企業より<strong>医薬品規制当局の動向</strong>（変化が大きい場合）を掲載。
      </div>
    </header>


    <section class="category-section category-pipeline">
      <h2 class="category-header">
        <span class="badge"></span>
        Pipeline
      </h2>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/manufacturing/abbvie-us-investment-tear-splashes-380m-2-new-api-plants-illinois-home-campus" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/manufacturing/abbvie-us-investment-tear-splashes-380m-2-new-api-plants-illinois-home-campus&quot; hreflang=&quot;en&quot;&gt;AbbVie advances US expansion with $380M for 2 new North Chicago API plants&lt;/a&gt;</a></h3>
        <p class="summary">The new plants are the latest in a string of recent investments AbbVie has made in U.S. manufacturing, filling out the company&#x27;s plan to infuse $100 billion into its American operations over the next …</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/manufacturing/abbvie-us-investment-tear-splashes-380m-2-new-api-plants-illinois-home-campus" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/roche-halts-development-enspryng-duchenne-muscular-dystrophy" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/roche-halts-development-enspryng-duchenne-muscular-dystrophy&quot; hreflang=&quot;en&quot;&gt;Roche halts development of Enspryng in Duchenne muscular dystrophy&lt;/a&gt;</a></h3>
        <p class="summary">Roche’s Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder. But the company’s efforts to expand its use to a new indication is coming up short.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/roche-halts-development-enspryng-duchenne-muscular-dystrophy" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/europe-pumps-brakes-us-trade-deal-after-supreme-court-decision-tanks-emergency-tariffs" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/europe-pumps-brakes-us-trade-deal-after-supreme-court-decision-tanks-emergency-tariffs&quot; hreflang=&quot;en&quot;&gt;Europe pumps brakes on US trade deal after Supreme Court decision, Trump tirade&lt;/a&gt;</a></h3>
        <p class="summary">With the Supreme Court’s rebuke of President Donald Trump’s emergency tariffs Friday, the U.S. administration’s international trade agenda is facing a new threat. At least one major partner has pumped…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/europe-pumps-brakes-us-trade-deal-after-supreme-court-decision-tanks-emergency-tariffs" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/marketing/bayer-sues-jj-over-deeply-flawed-promotional-claims-touting-erleada-over-nubeqa" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/marketing/bayer-sues-jj-over-deeply-flawed-promotional-claims-touting-erleada-over-nubeqa&quot; hreflang=&quot;en&quot;&gt;Bayer sues J&amp;J over ‘deeply flawed’ promotional claims touting Erleada over Nubeqa&lt;/a&gt;</a></h3>
        <p class="summary">Bayer has filed a false advertising lawsuit taking issue with claims made by Johnson &amp; Johnson to pit their prostate cancer drugs against one another.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/marketing/bayer-sues-jj-over-deeply-flawed-promotional-claims-touting-erleada-over-nubeqa" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/manufacturing/cdmo-bora-leverages-growing-north-american-footprint-250m-five-year-manufacturing" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/manufacturing/cdmo-bora-leverages-growing-north-american-footprint-250m-five-year-manufacturing&quot; hreflang=&quot;en&quot;&gt;CDMO Bora locks in 5-year, $250M production agreement with GSK &lt;/a&gt;</a></h3>
        <p class="summary">With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/manufacturing/cdmo-bora-leverages-growing-north-american-footprint-250m-five-year-manufacturing" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/vanda-gains-2nd-new-drug-approval-many-months-nod-bysanti" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/vanda-gains-2nd-new-drug-approval-many-months-nod-bysanti&quot; hreflang=&quot;en&quot;&gt;Vanda, with FDA nod for Bysanti, gains 2nd new drug approval in as many months&lt;/a&gt;</a></h3>
        <p class="summary">Vanda Pharmaceuticals is riding a regulatory roller coaster over the last few months with two FDA approvals and one rejection. On Friday, the U.S. regulator signed off on Vanda&#x27;s Bysanti, an atypical …</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/vanda-gains-2nd-new-drug-approval-many-months-nod-bysanti" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/girding-against-keytruda-cliff-merck-splits-oncology-standalone-business-unit" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/girding-against-keytruda-cliff-merck-splits-oncology-standalone-business-unit&quot; hreflang=&quot;en&quot;&gt;Girding against Keytruda cliff, Merck splits oncology into standalone business unit&lt;/a&gt;</a></h3>
        <p class="summary">The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck &amp; Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming med…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/girding-against-keytruda-cliff-merck-splits-oncology-standalone-business-unit" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/fortress-sells-fda-voucher-205m-after-zycubo-approval-last-month" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/fortress-sells-fda-voucher-205m-after-zycubo-approval-last-month&quot; hreflang=&quot;en&quot;&gt;Fortress sells FDA voucher for $205M after Zycubo approval last month&lt;/a&gt;</a></h3>
        <p class="summary">The trend of rising FDA voucher prices is continuing as 2026 plays out, with another transaction now valued at $200 million or more.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/fortress-sells-fda-voucher-205m-after-zycubo-approval-last-month" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/marketing/lilly-adds-multidose-zepbound-pens-self-pay-menu-after-fda-nod" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/marketing/lilly-adds-multidose-zepbound-pens-self-pay-menu-after-fda-nod&quot; hreflang=&quot;en&quot;&gt;Lilly adds multidose Zepbound pens to self-pay menu after FDA nod&lt;/a&gt;</a></h3>
        <p class="summary">About a month after securing a label expansion from the FDA for multidose pen versions of Zepbound, Eli Lilly is making the KwikPens available to self-paying users of its direct-to-consumer drug sales…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/marketing/lilly-adds-multidose-zepbound-pens-self-pay-menu-after-fda-nod" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/sponsored/obesity-power-rankings-who-will-challenge-lilly-and-novo" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/sponsored/obesity-power-rankings-who-will-challenge-lilly-and-novo&quot; hreflang=&quot;en&quot;&gt;Obesity Power Rankings: Who will challenge Lilly and Novo?&lt;/a&gt;</a></h3>
        <p class="summary">In what will be the industry’s most competitively contested market, FENIX power ranks the Top 10 obesity players positioned to outperform</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/sponsored/obesity-power-rankings-who-will-challenge-lilly-and-novo" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>
    </section>

    <footer style="margin-top: 40px; padding-top: 20px; border-top: 1px solid var(--border); font-size: 0.75rem; color: var(--text-muted);">
      Pharma Daily Brief — PiercePharma 朝刊 | 米国中心・欧州大手・中国規制を含む医薬・バイオ業界の重要ニュース
    </footer>
  </div>
</body>
</html>